Sanofi and Regeneron's Kevzara (sarilumab) Fails in P-III Trial for Patients with COVID-19 in the US
Shots:
- The P-III study assessing Kevzara (400mg) + BSC vs BSC in 194 patients with COVID-19 requiring mechanical ventilation did not meet it's 1EPs & 2EPs
- Based on the results- the companies have stopped the US-based study that includes the second cohort of patients receiving a higher dose of Kevzara (800 mg)
- The IDMC is managing both the Regeneron-led US trial and the Sanofi-led trial outside of the US and has recommended that the trial outside the US using a different dosing regimen should continue with its anticipated results in Q3’20
Click here to read full press release/ article | Ref: Sanofi | Image: WSJ
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
